We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Integer (ITGR) Q2 Earnings
Read MoreHide Full Article
The upcoming report from Integer (ITGR - Free Report) is expected to reveal quarterly earnings of $1.24 per share, indicating an increase of 8.8% compared to the year-ago period. Analysts forecast revenues of $438.15 million, representing an increase of 9.5% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Integer metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Sales- Non-Medical' should come in at $8.52 million. The estimate indicates a change of -22.1% from the prior-year quarter.
The average prediction of analysts places 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' at $168.14 million. The estimate points to a change of +9.6% from the year-ago quarter.
Analysts predict that the 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' will reach $25.06 million. The estimate suggests a change of -7.9% year over year.
Based on the collective assessment of analysts, 'Sales- Medical Sales- Cardio & Vascular' should arrive at $236.43 million. The estimate indicates a year-over-year change of +13.4%.
The consensus estimate for 'Sales- Total Medical Sales' stands at $429.74 million. The estimate points to a change of +10.4% from the year-ago quarter.
Shares of Integer have experienced a change of +8.5% in the past month compared to the -0.3% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), ITGR is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Integer (ITGR) Q2 Earnings
The upcoming report from Integer (ITGR - Free Report) is expected to reveal quarterly earnings of $1.24 per share, indicating an increase of 8.8% compared to the year-ago period. Analysts forecast revenues of $438.15 million, representing an increase of 9.5% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Integer metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Sales- Non-Medical' should come in at $8.52 million. The estimate indicates a change of -22.1% from the prior-year quarter.
The average prediction of analysts places 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' at $168.14 million. The estimate points to a change of +9.6% from the year-ago quarter.
Analysts predict that the 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' will reach $25.06 million. The estimate suggests a change of -7.9% year over year.
Based on the collective assessment of analysts, 'Sales- Medical Sales- Cardio & Vascular' should arrive at $236.43 million. The estimate indicates a year-over-year change of +13.4%.
The consensus estimate for 'Sales- Total Medical Sales' stands at $429.74 million. The estimate points to a change of +10.4% from the year-ago quarter.
View all Key Company Metrics for Integer here>>>
Shares of Integer have experienced a change of +8.5% in the past month compared to the -0.3% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), ITGR is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>